Carbon Dioxide Levels for Anesthesia in Children
Trial Summary
What is the purpose of this trial?
Carbon Dioxide (CO2) is a by-product of metabolism and is removed from the body when we breathe out. High levels of CO2 can affect the nervous system and cause us to be sleepy or sedated. Research suggests that high levels of CO2 may benefit patients who are asleep under anesthesia, such as by reducing infection rates, nausea, or recovery from anesthesia . CO2 may also reduce pain signals or the medication required to keep patients asleep during anesthesia; this has not been researched in children. During general anesthesia, anesthesiologists keep patients asleep with anesthetic gases or by giving medications into a vein. These drugs can depress breathing; therefore, an anesthesiologist will control breathing (ventilation) with an artificial airway such as an endotracheal tube. Changes in ventilation can alter the amount of CO2 removed from the body. The anesthesiologist may also monitor a patient's level of consciousness using a 'Depth of Anesthesia Monitor' such as the Bispectral Index (BIS), which analyzes a patient's brain activity and generates a number to tell the anesthesiologist how asleep they are. The investigator's study will test if different levels of CO2 during intravenous anesthesia are linked with different levels of sedation or sleepiness in children, as measured by BIS. If so, this could reduce the amount of anesthetic medication the child receives. Other benefits may be decreased medication costs, fewer side effects, and a positive environmental impact by using less disposable anesthesia equipment.
Research Team
Christopher A Chin, MBBS, FRCA, FRCP, MA
Principal Investigator
University of British Columbia
Eligibility Criteria
This trial is for children aged 3-11 years who need anesthesia for non-painful or minimally painful procedures, like certain ear surgeries or dental work with local anesthetics. They should be generally healthy (ASA status I and II) and the procedure should last at least 90 minutes to allow time for testing.Inclusion Criteria
Treatment Details
Interventions
- End Tidal Carbon Dioxide Concentration Monitoring (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
Dr. Christopher Haqq
University of British Columbia
Chief Medical Officer since 2019
MD, University of British Columbia
Bekki Bracken Brown
University of British Columbia
Chief Executive Officer since 2023
Bachelor's degree from Duke University